Device Trial Radar · NCT04386785
Venclose RF Ablation System for the Treatment of IPVs
Last checked: Nov 19, 2026Latest source record: May 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
May 23, 2020
Primary completion
Apr 13, 2021
Study completion May 13, 2021
Sponsor
- Lead sponsor
- Venclose, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 13, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A feasibility study conducted in patients with incompetent (i.e. refluxing) perforator veins were treated using the Venclose RF Ablation System.
Conditions
- Chronic Venous Insufficiency
Interventions
Radiofrequency (RF) Thermal Ablation of Incompetent Perforator VeinsDevice
The physician operator will access the IPV and advance the device to the target treatment position using ultrasound guidance. After providing local anesthesia to the vein and surrounding tissues, thermal ablation energy is delivered to the vein wall. After treatment is complete, the device is removed and vessel closure confirmed with duplex ultrasound.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety: AEs, SAEs, ADEs, SADEs, UADEsTime frame: 3-day post-procedure
- Safety: AEs, SAEs, ADEs, SADEs, UADEsTime frame: 15-day post-procedure
- Safety: AEs, SAEs, ADEs, SADEs, UADEsTime frame: 30-day post-procedure
4 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Vein Center of East Texas at CardioStream
Tyler, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.